(NasdaqGM:SHLS), – Record Quarterly Revenue of $135.8 million, an increase of 32.9% year over year – – Gross Margin of 37.0% – – Operating Profit of $18.7 million – – Adjusted EBITDA1 of $32.0 million – – Record Backlog and Awarded Orders of $720.9 million – – Provides Fourth Quarter and Full Year 2025 Revenue […]
EXTON, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical, a leader in innovative respiratory care neurostimulation technologies, today announced the first six patients enrolled in the groundbreaking STARI (STimulation to Activate RespIration) clinical trial. STARI is evaluating the safety, effectiveness, and feasibility of Lungpacer's next-generation AeroNova system designed to deliver continual temporary transvenous diaphragm
Alexandria, Va., Nov. 04, 2025 (GLOBE NEWSWIRE) — The National Community Pharmacists Association (NCPA), in collaboration with the University of Southern California (USC), today unveiled an interactive, user-friendly pharmacy shortage area mapping tool available to the general public for the first time. Previously accessible only to select individuals and organizations, the tool can now be
CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Amplify ETFs, a leading provider of breakthrough ETF solutions, announces the launch of the Amplify Solana 3% Monthly Option Income ETF (SOLM). SOLM is the latest crypto-linked product addition to Amplify's growing YieldSmart(TM) ETFs suite–a family of advanced covered call options-based ETFs focused on balancing income and capital
(NasdaqGM:FOLD), Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company
(NasdaqGM:OCUL), SOL-R, the second registrational trial of AXPAXLI(TM) in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL,
(NASDAQ:LGIH), THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2025. “We are pleased with our third quarter results, which met our stated guidance and reflect the disciplined execution of our teams as we continue
BERKELEY HEIGHTS, N. J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining additional safety data and impact of prior lines of therapy from the Company's Phase 2 PRIMO trial at the upcoming
(NASDAQ:TNXP), Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 Novel immunomodulatory regimen designed to reduce calcineurin inhibitor exposure and improve outcomes Dimeric Fc-modified mAb TNX-1500 selectively targets cell-associated CD40L with once-monthly dosing CHATHAM, N.J., Nov. 04, 2025 (GLOBE
(PinkSheets:FAVO),(Pinksheets:FAVO), FORT LAUDERDALE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — via IBN – Stewards Inc. (OTC: FAVO), a diversified financial company operating across private credit, real assets and digital finance, today announces a $10 million strategic partnership with Dolomite, a decentralized finance (DeFi) technology provider specializing in on-chain liquidity management, lending and tokenized asset infrastructure.